Technical Analysis for SYRS - Syros Pharmaceuticals, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 4.54 | -3.81% | -0.18 |
Earnings due: May 8
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 200 DMA | Bearish | 0.00% | |
| MACD Bearish Signal Line Cross | Bearish | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| NR7-2 | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| NR7 | Range Contraction | -3.81% | |
| Wide Bands | Range Expansion | -3.81% | |
| Fell Below 20 DMA | Bearish | -11.15% | |
| Wide Bands | Range Expansion | -11.15% |
| Alert | Time |
|---|---|
| Possible NR7 | about 14 hours ago |
| Down 5% | about 15 hours ago |
| 60 Minute Opening Range Breakdown | about 17 hours ago |
| Down 3% | about 17 hours ago |
| 200 DMA Resistance | about 17 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 05/08/2024
Syros Pharmaceuticals, Inc. Description
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing medicines that control genes to transform the lives of patients with cancer, immune-mediated diseases, and other diseases. The company's gene control platform identifies gene control targets linked to genomically defined patient populations and drugging gene control targets; identifies potential new drug targets across a range of diseases; provides lens for diagnosing and segmenting patients, including those with complex/multi-factorial diseases; and allows users to advance a wave of medicines with the potential to influence multiple drivers of disease through a single target. Its pipeline includes SY-1425, a selective RARa agonist for genomically defined subsets of patients with relapsed or refractory acute myeloid leukemia and relapsed high-risk myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor for acute leukemia. Syros Pharmaceuticals, Inc. was formerly known as LS22, Inc. Syros Pharmaceuticals, Inc. was founded in 2011 and is based in Cambridge, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Disease Medication Acute Myeloid Leukemia Leukemia Myelodysplastic Syndrome Immune Mediated Diseases Acute Leukemia Refractory Acute Myeloid Leukemia
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 8.17 |
| 52 Week Low | 2.0902 |
| Average Volume | 217,551 |
| 200-Day Moving Average | 4.72 |
| 50-Day Moving Average | 6.27 |
| 20-Day Moving Average | 5.32 |
| 10-Day Moving Average | 5.21 |
| Average True Range | 0.48 |
| RSI (14) | 35.90 |
| ADX | 19.24 |
| +DI | 19.16 |
| -DI | 28.30 |
| Chandelier Exit (Long, 3 ATRs) | 5.07 |
| Chandelier Exit (Short, 3 ATRs) | 5.83 |
| Upper Bollinger Bands | 6.48 |
| Lower Bollinger Band | 4.16 |
| Percent B (%b) | 0.16 |
| BandWidth | 43.61 |
| MACD Line | -0.36 |
| MACD Signal Line | -0.36 |
| MACD Histogram | -0.0052 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 5.02 | ||||
| Resistance 3 (R3) | 5.03 | 4.87 | 4.94 | ||
| Resistance 2 (R2) | 4.87 | 4.75 | 4.87 | 4.91 | |
| Resistance 1 (R1) | 4.71 | 4.68 | 4.63 | 4.70 | 4.89 |
| Pivot Point | 4.55 | 4.55 | 4.52 | 4.55 | 4.55 |
| Support 1 (S1) | 4.39 | 4.43 | 4.31 | 4.38 | 4.19 |
| Support 2 (S2) | 4.23 | 4.36 | 4.23 | 4.17 | |
| Support 3 (S3) | 4.07 | 4.23 | 4.14 | ||
| Support 4 (S4) | 4.06 |
